Peconic Partners’s Grace Therapeutics GRCE Stock Holding History

Peconic Partners’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-7,292	Closed	-$858K	–	71
2019 Q4	$858K	Hold	7,292	–	–	0.18%	30
2019 Q3	$662K	Buy	+7,292	New	+$675K	0.15%	29

Other funds holding GRCE

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Oppenheimer & Co New York $8.21B AUM 28.81% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

JLBC

J.L. Bainbridge & Co Sarasota, Florida $1.27B AUM 26.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Peconic Partners's GRCE Position: Q1 2020 in Review

Peconic Partners sold out of Grace Therapeutics (GRCE) in Q1 2020, closing a stake of 7,292 shares — an estimated $858K sold.

Peconic Partners first reported a position in GRCE in Q3 2019 and held it in 2 quarters. The position peaked at $858K in Q4 2019. 26 funds tracked by Wall St. Rank hold GRCE as of Q1 2020.

Peconic Partners reported no remaining Grace Therapeutics position as of Q1 2020 after selling out during the quarter.
Peconic Partners sold 7,292 Grace Therapeutics shares in Q1 2020, an estimated $858K.
Peconic Partners first reported a position in Grace Therapeutics in Q3 2019 and held it in 2 quarters.
Peconic Partners's Grace Therapeutics position peaked at $858K in Q4 2019.
26 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2020.

Based on Peconic Partners's 13F filing for Q1 2020, filed 15 May 2020.